Most Read Articles
29 Nov 2018
Pulmonary hypertension (PH) is associated with underlying risk factors in children with congenital hyperinsulinism (HI) treated with diazoxide, reports a study. Other adverse events, however, do not show any identifiable risk profile.
18 Jan 2019
Azithromycin treatment in children with recurrent asthma-like symptoms acutely disrupts gut microbiota composition, a recent study has found.

Original New Drug Application Approvals by US FDA (16 - 30 November 2017)

30 Nov 2017

New drug applications approved by US FDA as of 16-30 November which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

HEMLIBRA

  • Active Ingredient(s): Emicizumab
  • Strength: 30mg/ml; 60mg/0.4ml; 105mg/0.7ml; 150mg
  • Dosage Form: Injectable;injection
  • Company: Genentech Inc
  • Approval Date: November 16, 2017
  • Submission Classification: Not available
  • Indication(s): Indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
  • Approved Label: 11/16/2017(PDF)

PALONOSETRON
  • Active Ingredient(s): Palonosetron Hydrochloride
  • Strength: 0.25mg/ml
  • Dosage Form: Injectable;injection
  • Company: Fresenius Kabi USA
  • Approval Date: November 21, 2017
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated in adults for:
    • Moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses. 
    • Highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses.
    • Prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated.
  • Approved Label: 11/21/2017(PDF)
JULUCA
  • Active Ingredient(s): Dolutegravir;Rilpivirine
  • Strength: 50mg;25mg
  • Dosage Form: Tablet;oral
  • Company: VIIV Hlthcare
  • Approval Date:  November 21, 2017
  • Submission Classification: Type 4 - New Combination
  • Indication(s): Indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA.
  • Approved Label: 11/21/2017(PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2018
Pulmonary hypertension (PH) is associated with underlying risk factors in children with congenital hyperinsulinism (HI) treated with diazoxide, reports a study. Other adverse events, however, do not show any identifiable risk profile.
18 Jan 2019
Azithromycin treatment in children with recurrent asthma-like symptoms acutely disrupts gut microbiota composition, a recent study has found.